Biofrontera supplements proxy statement reclassifying two proposals as routine matters for broker voting

Biofrontera Inc.

NYSE determined Proposal Nos. 2 and 3 are routine; brokers may vote without instructions, reversing earlier disclosure.
Proposal No. 2 increases authorized common shares from 35M to 70M; Proposal No. 3 is an adjournment measure.
Proxies already received remain valid unless revoked; annual meeting still set for June 12, 2025.
Only Proposal No. 4 (ratification of auditor) was previously listed as routine in the original proxy statement.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.